Greenlight Biosciences

Greenlight Biosciences was founded in 2008 by Andrey Zarur and Marta Ortega-Valle with a mission to harness the power of RNA to address critical challenges in agriculture and human health. The company set out to develop innovative RNA-based solutions that could transform the way we approach pest control and crop management, aiming for a more sustainable and equitable food system.

In its journey, Greenlight Biosciences achieved a significant milestone in August 2021 by going public through a $1.2 billion SPAC merger with Environmental Impact Acquisition Corp. This move provided the company with the necessary capital to expand its research and development efforts and bring its groundbreaking products to a broader market.

Continuing its trajectory of growth and innovation, Greenlight Biosciences announced in May 2023 that it would be acquired by Fall Line Capital in a go-private transaction. This acquisition marked a new chapter for the company, allowing it to focus on long-term strategic goals without the pressures of public market fluctuations.

Throughout its history, Greenlight Biosciences has remained committed to its founding vision, leveraging RNA technology to create solutions that not only improve agricultural productivity but also promote environmental sustainability. The company's journey reflects a steadfast dedication to innovation and impact, positioning it as a leader in the field of biosciences.